查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844154

多发性骨髓瘤治疗市场按药物类别、给药途径、分销管道和产品类型划分－2025年至2032年全球预测

Multiple Myeloma Therapeutics Market by Drug Class, Mode Of Administration, Distribution Channel, Product Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，多发性骨髓瘤治疗市场将成长至 404.8 亿美元，复合年增长率为 7.35%。

关键市场统计数据
基准年 2024 229.5亿美元
预计年份：2025年 246亿美元
预测年份 2032 404.8亿美元
复合年增长率 (%) 7.35%

观点全面介绍了科学突破、不断发展的治疗模式和支付方动态如何共同作用，重新定义多发性骨髓瘤的治疗路径。

多发性骨髓瘤治疗处于科学创新、不断发展的临床实践和复杂的商业动态的关键交汇点。细胞疗法、标靶抗体、小分子药物和递送方式的进步正在再形成治疗路径，并重新定义疗效、耐受性和长期疾病控制的预期。这些科学进步与治疗药物的生产、报销和交付方式的结构性变革同步发生，因此，相关人员更需要整合临床、监管和运营信息，以製定连贯的战略规划。

临床医生和医疗系统正在探索更广泛的治疗方法方案，从高度专业的细胞疗法到传统的蛋白酶体抑制剂和免疫调节剂。支付者和政策制定者正根据有关疗效和持久性的证据，不断完善医保覆盖框架，并开展基于结果的合约试点计画。同时，製造商正努力应对更漫长、更复杂的先进疗法研发路径，这需要同时投资于生产能力、低温运输物流和专业人才培育。这些动态共同带来了机会和风险：机会在于为患者带来变革性益处并获得差异化的商业性价值；风险则与供应连续性、价格压力和推广障碍有关。

本介绍涵盖了不断变化的行业格局、关税对供应链和成本的影响、按治疗层级和交付渠道分類的细分见解、区域细微差别、竞争格局、为行业领导者提供的可操作建议以及调查方法——所有这些都是为了向经营团队提供平衡的、基于证据的观点，以指导近期决策和多年规划。

近期科学突破、监管灵活性和商业性创新如何重塑多发性骨髓瘤的治疗路径、取得模式和竞争需求

多发性骨髓瘤的治疗格局正在经历一场变革性的转变，这得益于一系列科学突破、监管灵活性和创新商业模式的共同推动。细胞疗法和新一代免疫疗法正在拓展临床可行治疗方法的边界，治疗模式也正从以细胞毒性药物为主的序贯治疗方案演变为旨在实现更深层次缓解和延长无进展生存期的持续靶向治疗。生物标记主导的患者筛选以及诊断准确性的同步提升，使得更合理的治疗顺序和联合策略成为可能，提高了治疗的个人化程度，同时也增加了临床决策的复杂性。

监管机构越来越倾向于采用加速审批途径和真实世界证据来核准并扩大附加檔，从而缩短从概念验证的时间，同时也增加了对核准后证据生成和药物安全检测的需求。在商业性，製造商正在尝试创新的合约结构，例如基本契约和多方相关人员风险分担机制，以平衡领先定价和长期价值交付。在营运方面，高成本、产能受限治疗方法的兴起正在推动製造商、专科医疗机构和物流合作伙伴之间的合作，以管理生产规模的扩大和确保患者公平获得治疗。

成熟的产品组合，例如蛋白酶体抑制剂和免疫调节剂，正透过配方改进和给药途径创新进行优化，而研发密集型企业则优先发展细胞疗法和双特异性抗体平台。医疗保健系统也正在进行类似的调整，投资建设能够整合新型治疗方法的专科中心和诊疗路径，同时兼顾预算和基础设施的限制。最终，市场环境呈现出快速技术创新、相关人员之间日益增强的相互依存以及与协调生产、临床应用和报销相关的执行风险增加的特征。

了解新关税措施对下游供应链、定价和营运的影响，以及如何维持策略采购和製造的选择性准入和商业性可行性。

2025年关税政策为依赖跨境供应链和专业生产投入的治疗产品带来了新的营运和商业复杂性。进口关税的引进或调整不仅影响成品药，还会影响活性生物製药材料、一次性生物加工设备和低温运输物流服务原料药。因此，製造商和经销商正在重新评估其筹资策略、供应商合约和库存政策，以在限製成本影响的同时，维持供应的连续性。

关税环境鼓励企业进行策略转型，转向近岸外包和供应商网路多元化，这可以降低关税波动和地缘政治风险的影响，但合格的新供应商可能需要资本投资和更长的前置作业时间。此外，更高的进口关税将提升国内生产能力的重要性，并加强与合约研发受託製造机构（CD&M）的伙伴关係，这些机构可以将供应链中的某些环节纳入企业内部生产。对于生产产量比率、身分控制和低温运输管理至关重要的先进疗法而言，关税引发的物流和零件成本变化可能会增加营运复杂性，并延缓患者治疗能力的提升。

从定价和报销的角度来看，关税带来的成本压力要求製造商积极与支付方沟通，建构能够体现实际价值并在相关人员之间分散风险的商业性安排。製造商应考虑情境规划，量化关税对毛利率的潜在成本影响，并确定缓解措施，例如配方调整、包装设计修改和物流优化，以减少对受关税影响的原材料的依赖。摘要：2025年的关税情势凸显了策略性供应链弹性规划、合约重新谈判以及对本地能力进行有针对性投资的必要性，以维持市场准入并保障商业性可行性。

针对不同药物类别、给药途径、分销管道和产品类型的细分市场策略要务将驱动投资和商业化优先事项。

细分市场层面的洞察揭示了不同治疗类别、给药途径、通路和产品类型所面临的差异化策略要务。就药物类别而言，CAR-T疗法展现出独特的开发和商业化模式，其特点是个人化生产、复杂的物流和卓越中心交付模式；而组蛋白去乙酰化酶抑制剂仍然是一类重要的辅助治疗药物，在耐受性和组合方案方面具有发展潜力。免疫调节剂在基础疗法中继续发挥核心作用，并透过新型製剂和联合用药研究进行生命週期管理。特别是，蛋白酶体抑制剂，如Bortezomib、Carfilzomib和Ixazomib，其给药方案、毒性和实际用药依从性各不相同，这会影响临床医生的选择。

按剂型划分，可以发现人们越来越倾向于尽可能以患者为中心的给药方式。静脉注射对于许多有效的生物製药和输液疗法仍然至关重要，而口服疗法因其便利性和长期维持治疗的优势而备受青睐，但也带来了依从性管理和药物相互作用方面的挑战。从分销管道动态来看，医院药房在住院药物和输液药物方面仍然发挥着重要作用，专科药房在管理复杂治疗方法和协调患者支持服务方面扮演着核心角色，而零售药房则在口服药物和维持治疗药物的配发方面发挥作用，这会影响患者依从性计划和自付费用结构。

最后，品牌学名药按产品类型划分，其商业策略也各不相同。学名药和生物相似药则着重于成本竞争、纳入医保目录策略以及作为维持治疗或专利到期后的快速上市。弥合这些细分市场之间的鸿沟，有助于更清晰地了解在生产规模、患者支持和循证医学证据生成方面的投资，如何才能对药物的接受度、依从性和长期治疗定位产生最显着的影响。

比较美洲、中东和非洲以及亚太地区的区域采纳率、基础设施和报销情况，以确定准入途径和战略投资方向。

区域动态将影响新型多发性骨髓瘤疗法的推广速度和运作前提。美洲地区正快速推进创新治疗方法的临床应用，并持续拥有完善的健保报销体系，支持早期准入计画。欧洲、中东和非洲地区（EMEA）的推广速度将因监管协调、区域采购机制和医疗基础设施的差异而有所不同：高所得的西方市场将加速推广，而新兴市场则优先考虑成本效益高且可扩展的解决方案。

亚太地区的需求驱动因素错综复杂。一些市场在国家对先进製造能力的投资推动下，正加速新型生技药品和细胞疗法的临床应用；而其他市场则优先考虑在地化生产和成本控制。不同地区患者族群特征、併发症模式及医疗服务模式的差异，都会影响理想的产品特性。例如，门诊系统优先考虑口服给药的便利性，而住院模式则强调输注效率。供应链韧性和区域监管沟通策略必须根据当地的基础设施实际情况进行调整，以确保患者能够获得治疗并实现永续的商业化。

因此，跨区域计画必须整合区域性证据产生、适应性定价策略，并在适当情况下投资于区域生产或填充能力。与区域卓越中心、支付方和患者权益组织建立合作关係可以加快接受度和普及率，而透明的价值沟通和灵活的伙伴关係结构对于应对不同的报销理念和预算限制至关重要。

竞争优势日益集中在可扩展的生产製造、循证医学证据产生、支付方参与以及能够加速患者获得医疗服务并实现商业性可持续性的伙伴关係模式。

多发性骨髓瘤治疗公司之间的竞争动态日益取决于核心药物发现和临床开发以外的能力。在扩大复杂生物製药和细胞生产规模方面的组织灵活性、在以结果为导向的医保报销谈判中积累的经验，以及生成核准后真实世界证据的能力，如今已成为商业性成功的关键决定因素。专注于CAR-T和双特异性抗体等平台技术的公司正在投资于端到端的价值链（从载体生产和冷链物流到治疗中心培训），以缩短患者获得治疗的时间并提高治疗结果的一致性。

同时，拥有成熟蛋白酶体抑制剂、单株抗体和免疫调节剂等核心产品的现有企业正利用生命週期管理、联合用药试验和给药途径优化来巩固和拓展其治疗领域。策略联盟、许可协议和生产合作十分普遍，企业寻求利用外部专业知识来补充自身能力，例如细胞疗法生产、用于提高患者依从性的数位化健康解决方案以及用于复杂治疗协调的专科药房伙伴关係。併购活动体现出两种模式：一是旨在扩大生产规模的补充性收购；二是旨在建构涵盖药物发现、开发和商业化的一体化平台的大型策略交易。

从能力角度来看，成功的公司将融合深厚的临床开发专长、可扩展的生产营运、先进的卫生经济学证据产生能力以及能够适应当地支付方要求的灵活商业模式。在病患支援服务、依从性管理和数位化互动工具方面的领先地位，将透过展现能够简化病患病人历程、支持与支付方谈判以及药品目录定位的实际价值，进一步提升公司的竞争力。

为製造商和相关人员提供切实可行的策略，以确保供应弹性、循证价值、适应性合约和以患者为中心的服务模式，并加速这些模式的推广应用。

产业领导者应优先采取一系列切实可行的措施，使科学研究潜力与病患和商业性成果相契合。首先，应大力投资提升生产韧性和产能多元化，以降低供应链和关税风险。这包括筛选合格的替代供应商，并与支持生物製药批量生产和客製化生产的契约製造製造商建立策略联盟。同时，应将真实世界证据的生成纳入早期研发计划，以支持监管申报、核准后的附加檔扩展以及与支付方的基本契约，并确保数据收集的互通性和地域相关性。

第二，设计以病人为中心的给药模式，减轻病人用药负担，提高用药依从性。在临床上适宜的情况下，采用皮下或口服製剂，并整合数位化依从性工具和专科药局合作，以确保治疗的连续性。第三，采用弹性的商业合约模式，使定价与可衡量的疗效挂钩，并探索风险共担与订阅式安排，以促进药物可及性，同时保障长期收入来源。第四，调整区域策略，以因应基础设施和报销方面的差异，优先投资于关税和物流成本显着影响服务成本的市场中的本地生产和许可业务。

最后，在研发初期，应整合监管、临床、供应链和商业团队，并加强跨职能能力，以预测推广障碍并制定切实可行的上市计画。领导阶层也应与卓越中心和患者权益组织建立伙伴关係，以建立信任并加速临床应用。总而言之，这些建议措施将降低执行风险，支持永续的药物获取，并使公司能够将科学进步转化为持续的患者和股东价值。

研究途径方法，结合二手文献综述和相关人员访谈，检验了临床、营运和商业性影响。

支持这些见解的研究结合了结构化的二手资料回顾、有针对性的专家访谈和主题综合分析，从而构建了一个平衡且以实践为导向的观点。二手资料分析检视了同侪审查的临床文献、官方监管文件、临床试验註册库和现有政策声明，以梳理近期核准、适应症扩展以及临床实践的变化。这些资讯来源提供了临床和监管背景信息，使我们能够专注于治疗机制、给药途径以及证据生成的需求，而无需依赖专有的市场规模或预测数据。

初步研究包括对相关人员，受访者包括临床意见领袖、医院药局主任、专科药局经理、物流和生产专家以及支付方顾问。访谈旨在揭示营运限制因素、实施困难以及关税和供应链变化带来的实际影响。研究对初步研究和次要研究的结果进行三角验证，以检验主题，并确保策略建议既反映宏观趋势，也反映实际营运状况。

我们透过与专家反覆举办综合分析和检验研讨会，挑战既有假设并完善结论，从而保持了分析的严谨性。调查方法涵盖了不断发展的先进医疗製造技术以及可能改变监管和报销格局的持续政策变化。在适当情况下，我们会专注于存在不确定性的领域，并鼓励持续收集证据和进行情境规划，以适应新的发展。

整合治疗创新、商业执行和政策动态，这些因素共同决定了多发性骨髓瘤患者获得治疗的速度和商业性成功率。

总之，多发性骨髓瘤的治疗格局呈现出快速的技术创新和复杂的营运及商业性需求。儘管科学进步正在拓展可行的治疗策略范围，但要实现大规模的患者获益，取决于生产製造、物流、支付方参与和临床应用等各个环节的整合执行。关税和供应链动态变化带来了新的压力，需要采取策略性采购、考虑近岸外包以及灵活的合约条款，以维持药物供应和利润率。

该报告按药物类别、给药途径、分销管道和产品类型，重点阐述了在实证实践、生产规模和患者支援方面进行投资最为有效的领域。区域差异性要求在定价、监管沟通和基础设施投资等方面采取与当地给药能力和支付方预期相适应的策略。能够将科学差异化与卓越营运、可靠的卫生经济学证据以及风险共用并展现长期价值的适应性商业模式相结合的机构，将在竞争中脱颖而出。

相关人员应持续关注监管动态，投资建设能够捕捉真实世界结果的数据系统，并在研发早期阶段协调跨职能规划，以优化产品上市和市场准入。透过将创新目标与实际执行相结合，治疗领域能够在复杂的商业性环境中加速改善患者疗效。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • BCMA标靶CAR T细胞疗法在復发性多发性骨髓瘤患者的快速应用
  • 将针对BCMA和GPRC5D的双特异性抗体平台扩展至早期临床试验
  • 在多发性骨髓瘤治疗中，微量残存疾病评估在指导个人化治疗决策的应用日益广泛
  • 过渡到一线四联诱导疗法，合併使用蛋白酶体抑制剂和单株抗体
  • 来自主要生物相似药的多发性骨髓瘤治疗竞争加剧，影响了定价趋势。
  • 新一代 CELMoD 的出现，在难治性病例中显示出优于现有 IMiD 的疗效。
  • 将真实世界证据与数位健康平台结合，以优化患者依从性和治疗效果

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 多发性骨髓瘤药物市场（依药物类别划分）

  • CAR-T疗法
  • 组蛋白去乙酰化酶抑制剂
  • 免疫调节药物
  • 单株抗体
  • 蛋白酶体抑制剂
    • Bortezomib
    • Carfilzomib
    • Ixazomib

9. 多发性骨髓瘤药物市场依给药途径划分

  • 静脉
  • 口服
  • 皮下

10. 多发性骨髓瘤药物市场（依分销管道划分）

  • 医院药房
  • 零售药房
  • 专科药房

第十一章：多发性骨髓瘤药物市场（依产品类型划分）

  • 品牌
  • 非专利的

12. 多发性骨髓瘤药物市场（依地区分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：多发性骨髓瘤药物市场（按组别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国多发性骨髓瘤药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Bristol-Myers Squibb Company
    • Johnson & Johnson
    • Takeda Pharmaceutical Company Limited
    • Amgen Inc.
    • Sanofi SA
    • GlaxoSmithKline plc
    • Karyopharm Therapeutics Inc.
Product Code: MRR-ED54C46E8354

The Multiple Myeloma Therapeutics Market is projected to grow by USD 40.48 billion at a CAGR of 7.35% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 22.95 billion
Estimated Year [2025] USD 24.60 billion
Forecast Year [2032] USD 40.48 billion
CAGR (%) 7.35%

A comprehensive introductory perspective on how scientific breakthroughs, evolving delivery models, and payer dynamics are converging to redefine multiple myeloma care pathways

Multiple myeloma therapeutics sit at a pivotal intersection of scientific innovation, clinical practice evolution, and complex commercial dynamics. Advances in cellular therapies, targeted antibodies, small molecules, and administration modalities are reshaping treatment pathways and redefining expectations for efficacy, tolerability, and long-term disease control. These scientific advances are occurring alongside structural changes in how therapies are manufactured, reimbursed, and delivered to patients, intensifying the need for stakeholders to synthesize clinical, regulatory, and operational intelligence into coherent strategic plans.

Clinicians and health systems are navigating a wider array of therapeutic choices that span highly specialized cell therapies to more conventional proteasome inhibitors and immunomodulatory agents. Payers and policy-makers are responding to evidence on value and durability with evolving coverage frameworks and outcome-based contracting pilots. Meanwhile, manufacturers are contending with longer, more complex development pathways for advanced therapies that require parallel investments in manufacturing capacity, cold-chain logistics, and specialized workforce training. Together, these dynamics create both opportunity and risk: opportunities to deliver transformative patient benefits and capture differentiated commercial value, and risks tied to supply continuity, pricing pressures, and adoption barriers.

This introduction frames the subsequent sections, which examine the landscape shifts, tariff-related impacts on supply chains and costs, segmentation-driven insights across therapeutic classes and delivery channels, regional nuances, competitive behavior, actionable recommendations for industry leaders, and the methodology underpinning the intelligence gathered. The aim is to equip executive teams with a balanced, operationally grounded view that can inform near-term decisions and multi-year planning.

How recent scientific breakthroughs, regulatory flexibility, and commercial innovation are reshaping therapeutic pathways, access models, and competitive imperatives in multiple myeloma

The therapeutic landscape for multiple myeloma is undergoing transformative shifts driven by a confluence of scientific breakthroughs, regulatory adaptability, and commercial model innovation. Cellular therapies and next-generation immunotherapies are extending the boundaries of what is clinically feasible, prompting treatment paradigms to evolve from sequential, cytotoxic-focused regimens toward durable, targeted approaches that aim for deeper remissions and longer progression-free intervals. Parallel enhancements in biomarker-driven patient selection and diagnostic precision are enabling more rational sequencing and combination strategies, increasing the complexity of clinical decision-making while improving personalization of care.

Regulators are increasingly open to accelerated pathways and real-world evidence to inform approvals and label expansions, which shortens the time from proof-of-concept to broader clinical access but elevates the need for robust post-approval evidence generation and pharmacovigilance. Commercially, manufacturers are experimenting with innovative contracting arrangements, including outcomes-based agreements and multi-stakeholder risk-sharing constructs, to balance upfront pricing with long-term value delivery. Operationally, the rise of high-cost, capacity-constrained therapies has catalyzed collaborations between manufacturers, specialized providers, and logistics partners to manage manufacturing scale-up and equitable patient access.

Taken together, these shifts are altering competitive dynamics, with research-intensive players prioritizing cell therapy and bispecific platforms while established product classes such as proteasome inhibitors and immunomodulatory agents are being optimized through formulation changes and administration route innovations. Health systems are likewise adapting by investing in specialized centers of excellence and care pathways that can integrate new therapies while managing budgetary and infrastructure constraints. The net effect is a market environment defined by rapid innovation, increasing interdependence among stakeholders, and heightened execution risk tied to manufacturing, clinical adoption, and reimbursement alignment.

Understanding the downstream supply chain, pricing, and operational implications of new tariff measures and how strategic sourcing and manufacturing choices can preserve access and commercial viability

Tariff policies in 2025 introduced a new layer of operational and commercial complexity for therapeutics that rely on cross-border supply chains and specialized manufacturing inputs. The introduction or recalibration of import tariffs affects not only finished pharmaceutical products but also critical components such as active pharmaceutical ingredients, biologic raw materials, single-use bioprocessing equipment, and cold-chain logistics services. As a result, manufacturers and distributors are reassessing sourcing strategies, supplier contracts, and inventory policies to preserve continuity of supply while containing cost impacts.

The tariff environment has prompted a strategic pivot toward nearshoring and diversification of supplier networks, which can mitigate exposure to tariff volatility and geopolitical risk but may require capital investment and longer lead times to qualify new suppliers. In addition, increased import duties elevate the relative importance of domestic manufacturing capacity and contract development and manufacturing organization partnerships that can internalize some supply chain stages. For advanced therapies, where manufacturing yields, chain-of-identity controls, and cold-chain management are critical, tariff-induced changes to logistics and component costs can translate into higher operational complexity and potentially slower scaling of patient throughput.

From a pricing and reimbursement perspective, tariff-driven cost pressures necessitate proactive engagement with payers to demonstrate real-world value and to structure commercial arrangements that distribute risk across stakeholders. Manufacturers should consider scenario planning that quantifies potential cost impacts of tariffs on gross margins and identifies mitigations such as formulation changes that reduce dependency on tariff-exposed inputs, redesigned packaging, and logistics optimization. In summary, the 2025 tariff landscape underscores the need for strategic supply chain resilience planning, contract renegotiation, and targeted investments in local capacity to preserve access and protect commercial viability.

Segmentation-driven strategic imperatives across drug classes, administration routes, distribution channels, and product types that dictate investment and commercialization priorities

Segment-level insights reveal differentiated strategic imperatives across therapeutic classes, routes of administration, distribution pathways, and product types. Within drug classes, CAR-T therapy represents a distinct development and commercialization paradigm characterized by individualized manufacturing, complex logistics, and center-of-excellence delivery models, while Histone Deacetylase Inhibitors remain an important adjuvant class with opportunities around tolerability and combination regimens. Immunomodulatory drugs continue to play a central role in backbone therapy and are subject to lifecycle management through new formulations and combination studies. Monoclonal antibodies and proteasome inhibitors maintain an essential position in treatment sequencing; notably, proteasome inhibitors such as Bortezomib, Carfilzomib, and Ixazomib each present different administration profiles, toxicity considerations, and real-world adherence implications that influence clinician choice.

Administration mode segmentation highlights the growing preference for patient-centric delivery where feasible: intravenous delivery remains indispensable for many high-efficacy biologics and infusion-based regimens, oral therapies gain traction for convenience and chronic maintenance settings but pose adherence and drug-drug interaction management challenges, and subcutaneous formulations are increasingly developed to reduce clinic time and resource burden. Distribution channel dynamics show that hospital pharmacies continue to be critical for inpatient and infusion-delivered products, specialty pharmacies are central for managing complex therapies and coordinating patient support services, and retail pharmacies play a role in dispensing oral and maintenance medications with implications for patient adherence programs and co-pay assistance structures.

Finally, product type differentiation between branded and generic offerings drives distinct commercial strategies. Branded developers focus on innovation, evidence generation for label expansion, and premium pricing strategies underpinned by differentiated clinical data, whereas generic entrants and biosimilars emphasize cost competitiveness, formulary placement tactics, and rapid adoption in maintenance or post-patent-loss settings. Bridging these segmentation lenses enables a clearer understanding of where investment in manufacturing scale, patient support, and evidence generation will have the most meaningful impact on uptake, adherence, and long-term therapeutic positioning.

Regional adoption, infrastructure, and reimbursement contrasts that determine access pathways and strategic investments across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape both the pace of adoption and the operational prerequisites for delivering novel multiple myeloma therapies. The Americas continue to be characterized by high clinical adoption for innovative modalities and an advanced reimbursement ecosystem that supports early access programs; this region also faces pronounced pricing scrutiny and payer-driven value frameworks that require robust real-world evidence and outcomes-based contracting. In Europe, Middle East & Africa, regulatory harmonization, regional purchasing mechanisms, and variable healthcare infrastructure lead to heterogenous adoption timelines, with high-income markets in Western Europe accelerating uptake while emerging markets prioritize cost-effective and scalable solutions.

Asia-Pacific exhibits a complex mosaic of demand drivers: certain markets demonstrate rapid clinical uptake of novel biologics and cell therapies supported by targeted national investments in advanced therapy manufacturing capacity, while others emphasize local production and cost containment. Across regions, differences in patient demographics, comorbidity patterns, and healthcare delivery models influence ideal product profiles, such as a premium on oral convenience in ambulatory care-dominated systems or an emphasis on infusion efficiency in hospital-centric models. Supply chain resilience and local regulatory engagement strategies must be tailored to regional infrastructure realities to ensure patient access and sustainable commercialization.

Cross-region planning should therefore integrate localized evidence generation, adaptive pricing strategies, and investments in regional manufacturing or fill-finish capabilities where appropriate. Establishing partnerships with regional centers of excellence, payers, and patient advocacy organizations can accelerate acceptance and uptake, while transparent value communication and flexible contracting structures are essential to navigate differing reimbursement philosophies and budget constraints.

Competitive differentiation is increasingly anchored in scalable manufacturing, evidence generation, payer engagement, and partnership models that accelerate patient access and commercial sustainability

Competitive dynamics among companies operating in multiple myeloma therapeutics are increasingly defined by capabilities beyond core discovery and clinical development. Organizational agility in scaling complex biologic and cellular manufacturing, experience in navigating outcome-focused reimbursement negotiations, and the capacity to generate post-approval real-world evidence are now central determinants of commercial success. Companies focused on platform technologies such as CAR-T or bispecific antibodies are investing in the end-to-end value chain-ranging from vector production and cryogenic logistics to training of treatment centers-in order to reduce time-to-patient and improve consistency of outcomes.

At the same time, incumbents with established proteasome inhibitors, monoclonal antibodies, or immunomodulatory backbones are leveraging lifecycle management, combination studies, and administration route optimization to defend and extend their therapeutic roles. Strategic alliances, licensing deals, and manufacturing partnerships are common as firms seek to complement internal capabilities with external expertise in cell therapy manufacturing, digital health solutions for adherence, and specialty pharmacy networks for complex therapy coordination. Mergers and acquisitions trends reflect a blend of bolt-on acquisitions to secure manufacturing scale and larger strategic transactions aimed at building integrated platforms across discovery, development, and commercialization.

From a capabilities perspective, companies that succeed will combine deep clinical development expertise, scalable manufacturing operations, sophisticated health economics evidence generation, and nimble commercial models that can adapt to region-specific payer requirements. Leadership in patient support services, adherence management, and digital engagement tools further differentiates companies by smoothing the patient journey and demonstrating real-world value that supports payer negotiations and formulary positioning.

Actionable strategies for manufacturers and stakeholders to secure supply resilience, evidence-driven value, adaptive contracting, and patient-centric delivery models that accelerate uptake

Industry leaders should prioritize a set of pragmatic actions that align scientific potential with deliverable patient and commercial outcomes. First, invest proactively in manufacturing resilience and capacity diversification to mitigate supply chain and tariff risks, including qualification of alternate suppliers and strategic partnerships with contract manufacturers to support both bulk and specialized biologic production. Concurrently, embed real-world evidence generation into early development plans to support regulatory submissions, post-approval label expansions, and value-based contracting with payers, ensuring that data collection is interoperable and geographically relevant.

Second, design patient-centric delivery models that reduce administration burden and enhance adherence. Where clinically appropriate, pursue subcutaneous or oral formulations and integrate digital adherence tools and specialty pharmacy coordination to maintain continuity of care. Third, adopt flexible commercial contracting approaches that align pricing to measurable outcomes, exploring risk-sharing and subscription-style agreements to facilitate access while protecting long-term revenue streams. Fourth, tailor regional strategies to account for differences in infrastructure and reimbursement, prioritizing investments in local manufacturing or licensing in markets where tariffs or logistics materially affect cost-to-serve.

Finally, strengthen cross-functional capabilities by integrating regulatory, clinical, supply chain, and commercial teams early in development to anticipate adoption barriers and create executable launch plans. Leadership should also cultivate partnerships with centers of excellence and patient advocacy organizations to build trust and accelerate clinical uptake. These recommended actions collectively reduce execution risk, support sustainable access, and enable companies to convert scientific advances into durable patient and shareholder value.

A rigorous mixed-methods research approach combining secondary literature synthesis and targeted stakeholder interviews to validate clinical, operational, and commercial implications

The research underpinning these insights combined structured secondary intelligence review, targeted expert interviews, and thematic synthesis to create a balanced, practice-oriented perspective. Secondary analysis included interrogation of peer-reviewed clinical literature, public regulatory filings, clinical trial registries, and available policy statements to map recent approvals, label expansions, and changes in clinical practice. These sources informed the clinical and regulatory context without relying on proprietary market sizing or forecasting data, enabling a focus on therapeutic mechanisms, administration modalities, and evidence generation imperatives.

Primary research involved semi-structured interviews with a cross-section of stakeholders, including clinical opinion leaders, hospital pharmacy directors, specialty pharmacy operators, logistics and manufacturing experts, and payer advisors. Interviews were designed to surface operational constraints, adoption pain points, and the practical implications of tariff and supply chain shifts. Findings from primary and secondary research were triangulated to validate themes and to ensure that strategic recommendations reflect both macro-level trends and on-the-ground operational realities.

Analytical rigor was maintained through iterative synthesis and validation workshops with domain experts to challenge assumptions and refine implications. Limitations of the methodology include the evolving nature of advanced therapy manufacturing technologies and ongoing policy changes that may alter the regulatory and reimbursement landscape. Where appropriate, the research highlights areas of uncertainty and recommends ongoing evidence collection and scenario planning to adapt to emerging developments.

Synthesis of therapeutic innovation, operational execution, and policy dynamics that together determine the pace of patient access and commercial success in multiple myeloma

In conclusion, the therapeutic landscape for multiple myeloma is characterized by rapid innovation coupled with intricate operational and commercial requirements. Scientific advances are expanding the range of viable therapeutic strategies, but realization of patient benefit at scale depends on integrated execution across manufacturing, logistics, payer engagement, and clinical adoption. Tariff and supply chain dynamics have introduced new pressures that necessitate strategic sourcing, nearshoring consideration, and contractual flexibility to preserve access and margins.

Segmentation across drug class, mode of administration, distribution channels, and product type highlights where investments in evidence generation, manufacturing scale, and patient support will be most impactful. Regional heterogeneity requires tailored approaches to pricing, regulatory engagement, and infrastructure investments to match local delivery capabilities and payer expectations. Competitive success will go to organizations that marry scientific differentiation with operational excellence, robust health economics evidence, and adaptive commercial models that share risk and demonstrate long-term value.

Moving forward, stakeholders should continue to monitor regulatory developments, invest in data systems that capture real-world outcomes, and coordinate cross-functional planning early in development to optimize launch and access. By aligning innovation objectives with pragmatic execution, the therapeutic community can accelerate meaningful improvements in patient outcomes while navigating the complex commercial landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of BCMA-targeted CAR T-cell therapies in relapsed myeloma patients
  • 5.2. Expansion of bispecific antibody platforms targeting BCMA and GPRC5D in early clinical trials
  • 5.3. Growing use of minimal residual disease assessment to guide personalized treatment decisions in myeloma
  • 5.4. Shift toward frontline quadruplet induction regimens combining proteasome inhibitors and monoclonal antibodies
  • 5.5. Increasing competition from biosimilar versions of key multiple myeloma biologics impacting pricing dynamics
  • 5.6. Emergence of next-generation CELMoD agents showing improved efficacy over existing IMiDs in refractory cases
  • 5.7. Integration of real-world evidence and digital health platforms to optimize patient adherence and outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multiple Myeloma Therapeutics Market, by Drug Class

  • 8.1. CAR-T Therapy
  • 8.2. Histone Deacetylase Inhibitor
  • 8.3. Immunomodulatory Drug
  • 8.4. Monoclonal Antibody
  • 8.5. Proteasome Inhibitor
    • 8.5.1. Bortezomib
    • 8.5.2. Carfilzomib
    • 8.5.3. Ixazomib

9. Multiple Myeloma Therapeutics Market, by Mode Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Multiple Myeloma Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Retail Pharmacy
  • 10.3. Specialty Pharmacy

11. Multiple Myeloma Therapeutics Market, by Product Type

  • 11.1. Branded
  • 11.2. Generic

12. Multiple Myeloma Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Multiple Myeloma Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Multiple Myeloma Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Bristol-Myers Squibb Company
    • 15.3.2. Johnson & Johnson
    • 15.3.3. Takeda Pharmaceutical Company Limited
    • 15.3.4. Amgen Inc.
    • 15.3.5. Sanofi S.A.
    • 15.3.6. GlaxoSmithKline plc
    • 15.3.7. Karyopharm Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. MULTIPLE MYELOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. MULTIPLE MYELOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MULTIPLE MYELOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 176. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 178. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 190. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 191. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 216. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 228. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 229. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 252. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 253. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 254. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 255. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 262. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 263. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 264. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 265. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 276. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 277. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 289. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 296. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 297. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 298. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 299. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)

TABL